BioPharmX Corporation (NASDAQ:BPMX) Expected to Announce Earnings of -$0.25 Per Share

Wall Street brokerages expect BioPharmX Corporation (NASDAQ:BPMX) to post earnings of ($0.25) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for BioPharmX’s earnings. BioPharmX reported earnings per share of ($0.50) during the same quarter last year, which would indicate a positive year over year growth rate of 50%. The firm is scheduled to report its next earnings report on Thursday, August 29th.

On average, analysts expect that BioPharmX will report full-year earnings of ($1.00) per share for the current fiscal year. For the next financial year, analysts forecast that the business will report earnings of ($0.75) per share. Zacks’ EPS calculations are an average based on a survey of analysts that cover BioPharmX.

BioPharmX (NASDAQ:BPMX) last announced its quarterly earnings results on Tuesday, June 11th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.13).

Shares of NASDAQ BPMX traded down $0.09 on Wednesday, hitting $0.70. The company’s stock had a trading volume of 164,429 shares, compared to its average volume of 615,241. BioPharmX has a 12-month low of $0.75 and a 12-month high of $6.75. The company has a 50 day simple moving average of $0.95.

BioPharmX Company Profile

BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC).

Further Reading: Stop Order Uses For Individual Investors

Get a free copy of the Zacks research report on BioPharmX (BPMX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for BioPharmX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioPharmX and related companies with's FREE daily email newsletter.